Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCelada, Lucía
dc.contributor.authorRUIZ-CANTADOR, JOSE
dc.contributor.authorda Silva Alves Pereira, Bianca Gabriela
dc.contributor.authorIglesias Felip, Carmela
dc.contributor.authorCasteràs, Anna
dc.contributor.authorArenillas, Carlota
dc.contributor.authorCalsina, Bruna
dc.contributor.authorDatta, Debayan
dc.contributor.authorGarcía-Galea, Eduardo
dc.contributor.authorfasani, roberta
dc.contributor.authorMoreno-Cárdenas, Ana Belén
dc.contributor.authorMiranda, Berta
dc.contributor.authorDienstmann, Rodrigo
dc.contributor.authorVillanueva Cardús, Josep
dc.contributor.authorCapdevila Castillon, Jaume
dc.contributor.authorNuciforo, Paolo
dc.contributor.authorDOS SUBIRA, LAURA
dc.contributor.authorToledo, Rodrigo
dc.date.accessioned2025-05-20T10:45:40Z
dc.date.available2025-05-20T10:45:40Z
dc.date.issued2025-05-01
dc.identifier.citationArenillas C, Celada L, Ruiz-Cantador J, Calsina B, Datta D, García-Galea E, et al. Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes. Cancer Discov. 2025 May 1;15(5):1037-62.
dc.identifier.issn2159-8290
dc.identifier.urihttp://hdl.handle.net/11351/13110
dc.descriptionGenetic; Human tumors; Systemic hypoxia
dc.description.abstractThis study explores parallels between systemic hypoxia adaptation in high-altitude populations and tumorigenesis. We identified EPAS1, a gene critical for hypoxia adaptation in populations such as Tibetans and Sherpas, as playing a similar adaptive role in tumors arising under hypoxic conditions. Tumors from patients with chronic hypoxia displayed impaired DNA repair and frequent emergence of EPAS1 variants, with frequencies reaching up to 90%, echoing the positive selection seen in high-altitude dwellers. Mechanistically, EPAS1 gain-of-function mutations promote COX4I2 expression, reducing cellular oxygen consumption and supporting tumor proliferation in hypoxia. Analysis of clinical data from patients with hypoxia revealed tissue-specific and time-sensitive tumorigenic effects, particularly impacting oxygen-sensitive cells in the postnatal period. Our findings suggest that EPAS1-driven adaptation mechanisms in high-altitude populations provide a model for understanding tumor evolution under hypoxic stress, highlighting how genetic adaptations to diverse stressors in natural populations may yield insights into tumorigenesis and cancer progression. Significance: This study reveals a broad convergence in genetic adaptation to hypoxia between natural populations and tumors, suggesting that insights from natural populations could enhance our understanding of cancer biology and identify novel therapeutic targets.
dc.language.isoeng
dc.publisherAmerican Association for Cancer Research
dc.relation.ispartofseriesCancer Discovery;15(5)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCàncer - Aspectes genètics
dc.subjectAdaptació (Fisiologia)
dc.subjectAnoxèmia
dc.subjectAltituds
dc.subject.meshNeoplasms
dc.subject.mesh/genetics
dc.subject.meshHypoxia
dc.subject.meshAltitude
dc.subject.meshAdaptation, Physiological
dc.subject.mesh/genetics
dc.titleConvergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1158/2159-8290.CD-24-0943
dc.subject.decsneoplasias
dc.subject.decs/genética
dc.subject.decshipoxia
dc.subject.decsaltitud
dc.subject.decsadaptación fisiológica
dc.subject.decs/genética
dc.relation.publishversionhttps://doi.org/10.1158/2159-8290.CD-24-0943
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Arenillas C] Biomarkers and Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Celada L] Health Research Institute of Asturias (ISPA), University of Oviedo, Oviedo, Spain. Institute of Oncology of Asturias (IUOPA), University of Oviedo, Oviedo, Spain. [Ruiz-Cantador J] Adult Congenital Heart Disease Unit, Department of Cardiology, Hospital Universitario La Paz, Madrid, Spain. [Calsina B] Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. [Datta D, Moreno-Cárdenas AB] Biomarkers and Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [García-Galea E] Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Fasani R, Nuciforo P] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Miranda-Barrio B] Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat Integrada de Cardiopaties Congènites de l’Adolescent i l’Adult, Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart), Amsterdam, the Netherlands. [Robles-Guirado JÁ, Villanueva J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Iglesias C] Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Dienstmann R] Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. University of Vic – Central University of Catalonia, Vic, Spain. [Capdevila J] Neuroendocrine and Endocrine Tumor Translational Research Program, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Grup de Tumors Gastrointestinals i Endocrins, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Casteràs A] Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Dos-Subirà L] Unitat Integrada de Cardiopaties Congènites de l’Adolescent i l’Adult, Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart), Amsterdam, the Netherlands. [Toledo RA] Biomarkers and Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
dc.identifier.pmid40199338
dc.identifier.wos001480529400014
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PID2021-126297OA-I00
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record